Daiichi Sankyo reported 18% year-on-year second-quarter revenue growth and 129% growth in core operating profit at actual currency rates. Full-year guidance was unchanged. Shares rallied 5% on Oct. 30 from the previous day’s close.
Daiichi Sankyo has a leading ADC platform, a cutting-edge modality for cancer treatments that improves upon the safety and efficacy of existing chemotherapy treatments.
After Enhertu, Datroway, and I-DXd, Daiichi Sankyo’s other ADCs are still early stage, and the competitive landscape for ADCs is heating up.
Metric | 4568 | AZN | 4519 |
|---|---|---|---|
Price/Earnings (Normalized) | 16.35 | 17.48 | 22.95 |
Price/Book Value | 2.96 | 5.51 | 5.63 |
Price/Sales | 2.26 | 4.67 | 8.32 |
Price/Cash Flow | 43.14 | 18.01 | 21.52 |
Metric | 4568 | AZN | 4519 |
|---|---|---|---|
Quick Ratio | 1.62 | 0.79 | 3.43 |
Current Ratio | 2.70 | 1.01 | 4.35 |
Interest Coverage | 12.11 | 8.25 | — |
Metric | 4568 | AZN | 4519 |
|---|---|---|---|
Return on Assets (Normalized) | 7.41% | 9.32% | 21.45% |
Return on Equity (Normalized) | 17.26% | 22.09% | 25.34% |
Return on Invested Capital (Normalized) | 13.58% | 14.75% | 25.34% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|^pF?Mhxv | LOCK|Rz | $1T | |||
| Johnson & Johnson JNJ | LOCK|W!!ddc | LOCK|ff | $675B | |||
| AbbVie Inc ABBV | LOCK|&hCD&yl | LOCK|#h | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|$j#$wYq | LOCK|^hX | $389B | |||
| Merck & Co Inc MRK | LOCK|@T<^^lj | LOCK|#kk | $363B | |||
| Novartis AG ADR NVS | LOCK|R>x%$>>V | LOCK|w$R | $304B | |||
| AstraZeneca PLC AZN | LOCK|@?@<&hkg | LOCK|mc@ | $288B | |||
| Amgen Inc AMGN | LOCK|wt#^tb< | LOCK|mr@ | $253B | |||
| Gilead Sciences Inc GILD | LOCK|W&D^%? | LOCK|D?> | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|h>^jRl | LOCK|^g | $180B |
United States